The Library
Browse by Warwick Author
Up a level |
Jump to: Cambridge University Hospitals NHS Foundation Trust | Cancer Research UK (CRUK) | Medical Research Council (Great Britain) (MRC) | NIHR Cambridge Biomedical Research Centre | National Institute for Health Research (Great Britain) (NIHR) | National Institute for Health Research Health Technology Assessment (Great Britain) (NIHR HTA) | University College London Hospitals Charities | University College, London | Wellcome Trust (London, England)
Number of items: 16.
Cambridge University Hospitals NHS Foundation Trust
Ford, Hugo, Marshall, A. (Andrea), Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda Y., Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary W., Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M. and Dunn, Janet A. (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. The Lancet Oncology, Volume 15 (Number 1). pp. 78-86. doi:10.1016/S1470-2045(13)70549-7 ISSN 1470-2045.
Cancer Research UK (CRUK)
Meads, David M., Marshall, A. (Andrea), Hulme, Claire T., Dunn, Janet A. and Ford, Hugo E. R. (2016) The cost effectiveness of docetaxel and active symptom control versus active symptom control alone for refractory oesophagogastric adenocarcinoma : economic analysis of the COUGAR-02 trial. PharmacoEconomics, 34 (1). pp. 33-42. doi:10.1007/s40273-015-0324-5 ISSN 1170-7690.
Corrie, Pippa G., Marshall, A. (Andrea), Dunn, Janet A., Middleton, Mark R., Nathan, Paul D., Gore, Martin, Davidson, Neville, Nicholson, Steve, Kelly, Charles G., Marples, Maria et al.
(2014)
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M) : preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
The Lancet Oncology, Volume 15
(Number 6).
pp. 620-630.
doi:10.1016/S1470-2045(14)70110-X
ISSN 1470-2045.
Ford, Hugo, Marshall, A. (Andrea), Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda Y., Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary W., Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M. and Dunn, Janet A. (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. The Lancet Oncology, Volume 15 (Number 1). pp. 78-86. doi:10.1016/S1470-2045(13)70549-7 ISSN 1470-2045.
Marshall, A. (Andrea), Altman, Douglas G., Royston, Patrick and Holder, Roger L. (2010) Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study. BMC Medical Research Methodology, Vol.10 (Article 7). doi:10.1186/1471-2288-10-7 ISSN 1471-2288.
Marshall, A. (Andrea), Altman, Douglas G., Holder, Roger L. and Royston, Patrick (2009) Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Medical Research Methodology, Vol.9 (Articl). doi:10.1186/1471-2288-9-57 ISSN 1471-2288.
Medical Research Council (Great Britain) (MRC)
Marshall, A. (Andrea), Altman, Douglas G., Royston, Patrick and Holder, Roger L. (2010) Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study. BMC Medical Research Methodology, Vol.10 (Article 7). doi:10.1186/1471-2288-10-7 ISSN 1471-2288.
NIHR Cambridge Biomedical Research Centre
Meads, David M., Marshall, A. (Andrea), Hulme, Claire T., Dunn, Janet A. and Ford, Hugo E. R. (2016) The cost effectiveness of docetaxel and active symptom control versus active symptom control alone for refractory oesophagogastric adenocarcinoma : economic analysis of the COUGAR-02 trial. PharmacoEconomics, 34 (1). pp. 33-42. doi:10.1007/s40273-015-0324-5 ISSN 1170-7690.
National Institute for Health Research (Great Britain) (NIHR)
Corrie, Pippa G., Marshall, A. (Andrea), Dunn, Janet A., Middleton, Mark R., Nathan, Paul D., Gore, Martin, Davidson, Neville, Nicholson, Steve, Kelly, Charles G., Marples, Maria et al.
(2014)
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M) : preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
The Lancet Oncology, Volume 15
(Number 6).
pp. 620-630.
doi:10.1016/S1470-2045(14)70110-X
ISSN 1470-2045.
Ford, Hugo, Marshall, A. (Andrea), Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda Y., Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary W., Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M. and Dunn, Janet A. (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. The Lancet Oncology, Volume 15 (Number 1). pp. 78-86. doi:10.1016/S1470-2045(13)70549-7 ISSN 1470-2045.
Ford, Hugo, Marshall, A. (Andrea), Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda Y., Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary W., Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M. and Dunn, Janet A. (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. The Lancet Oncology, Volume 15 (Number 1). pp. 78-86. doi:10.1016/S1470-2045(13)70549-7 ISSN 1470-2045.
National Institute for Health Research Health Technology Assessment (Great Britain) (NIHR HTA)
Stein, R. C., Makris, A., Hughes-Davies, L., Macpherson, I. R., Hall, P. S., Cameron, D. A., Earl, H. M., Pinder, S. E., Poole, C. J., Rea, D. W. et al.
(2018)
OPTIMA : A prospective randomized trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in early breast cancer.
Cancer Research, 78
(4).
Abstract OT1-06-01.
ISSN 0008-5472
doi:10.1158/1538-7445.SABCS17-OT1-06-01
Bartlett, John M. S., Bayani, Jane, Marshall, A. (Andrea), Dunn, Janet A., Campbell, Amy, Cunningham, Carrie, Sobol, Monika S., Hall, Peter S., Poole, Christopher J., Cameron, David A. et al.
(2016)
Comparing breast cancer multiparameter tests in the OPTIMA Prelim Trial : no test is more equal than the others.
Journal of the National Cancer Institute, 108
(9).
djw050.
doi:10.1093/jnci/djw050
ISSN 0027-8874.
University College London Hospitals Charities
Ford, Hugo, Marshall, A. (Andrea), Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda Y., Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary W., Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M. and Dunn, Janet A. (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. The Lancet Oncology, Volume 15 (Number 1). pp. 78-86. doi:10.1016/S1470-2045(13)70549-7 ISSN 1470-2045.
University College, London
Ford, Hugo, Marshall, A. (Andrea), Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda Y., Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary W., Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M. and Dunn, Janet A. (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. The Lancet Oncology, Volume 15 (Number 1). pp. 78-86. doi:10.1016/S1470-2045(13)70549-7 ISSN 1470-2045.
Wellcome Trust (London, England)
Ford, Hugo, Marshall, A. (Andrea), Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda Y., Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary W., Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M. and Dunn, Janet A. (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. The Lancet Oncology, Volume 15 (Number 1). pp. 78-86. doi:10.1016/S1470-2045(13)70549-7 ISSN 1470-2045.
This list was generated on Fri Mar 29 08:25:00 2024 GMT.